
ZURA Stock Forecast & Price Target
ZURA Analyst Ratings
Bulls say
Zura Bio is viewed favorably because its lead asset, tibulizumab, offers a differentiated BAFF x IL-17A mechanism that could break the efficacy ceiling in hidradenitis suppurativa while also showing orthogonal potential in polymyalgia rheumatica and systemic sclerosis. The near-term catalyst-rich setup is compelling, with TibuSHIELD enrollment of 247 versus a 225 target, results expected in late Oct./early Nov., and SSc readout in 1H27, all supported by $205.1MM in 2Q26 cash and a runway through at least YE28. The added PMR program, a planned Phase 2 start by year-end 2026, and modeled 2035E worldwide sales of $1.6B for tibulizumab reinforce a multi-indication growth story with meaningful upside from an underpenetrated autoimmune market.
Bears say
Zura Bio is a high-risk clinical-stage biotechnology company whose outlook is weighed down by the possibility that tibulizumab and the broader pipeline may fail to demonstrate sufficient efficacy or safety in target indications. Clinical or regulatory setbacks could halt development entirely, while an inability to achieve sales estimates would undermine the commercial case for its lead programs. Even if development progresses, tibulizumab faces competitive pressure from current and future therapies, and manufacturing or shipment disruptions could further impair execution.
This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ZURA Analyst Forecast & Price Prediction
Start investing in ZURA
Order type
Buy in
Order amount
Est. shares
0 shares